Identification of Hub Genes and Biomarkers between Hyperandrogen and Normoandrogen Polycystic Ovary Syndrome by Bioinformatics Analysis-Reference-Cited by-同舟云学术

Identification of Hub Genes and Biomarkers between Hyperandrogen and Normoandrogen Polycystic Ovary Syndrome by Bioinformatics Analysis

Published:2023-01 Issue:1 Volume:26 Page:126-134
ISSN:1386-2073
Container-title:Combinatorial Chemistry & High Throughput Screening
language:en
Short-container-title:CCHTS

Author:

Li Xiaodong¹,Hu Baoshan²,Zhang Tianwei³,Liu Yang³

Affiliation:

1. Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian 361003, P.R. China

2. Department of Orthopedics, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian 361003, P.R. China

3. Department of Anesthesiology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian 361003, P.R. China

Abstract

Background: The common and divergent genetic mechanisms of hyperandrogen (HA) and normoandrogen (NA) polycystic ovary syndrome (PCOS) are currently unknown. Objective: This study aimed to explore the hub genes and potential mechanisms of HA and NA PCOS through bioinformatics analysis. Methods: The GSE137684 dataset was downloaded from the Gene Expression Omnibus (GEO) database. The co-expressed genes and differentially expressed genes (DEGs) between HA and NA PCOS samples were functionally annotated by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. The protein-protein interaction (PPI) network of the DEGs was constructed and visualized using STRING and Cytoscape, respectively, and the hub genes were screened using the Cytohubba plug-in. The transcription factors (TFs) of these hub genes were identified with the JASPAR database, and the hub gene-TF regulatory network was constructed. Results: A total of 327 DEGs, including 191 upregulated and 136 downregulated genes, were identified in HA PCOS relative to NA PCOS. Ten hub genes were screened, of which MYC, CAV1, and HGF were mainly enriched in the Proteoglycans in the cancer pathway. In addition, 47 TFs were identified that were found to be involved in the regulation of hub genes. Conclusion: MYC, CAV1, and HGF are potential diagnostic biomarkers and therapeutic targets for HA PCOS.

Publisher

Bentham Science Publishers Ltd.

Subject

Organic Chemistry,Computer Science Applications,Drug Discovery,General Medicine

Reference32 articles.

1. Azziz R.; Introduction: Determinants of polycystic ova-ry syndrome. Fertil Steril 2016,106(1),4-5

2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic cri-teria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004,81(1),19-25

3. Sung Y-A.; Oh J-Y.; Chung H.; Lee H.; Hyperandrogenemia is implicated in both the metabolic and reproductive morbidi-ties of polycystic ovary syndrome. Fertil Steril 2014,101(3),840-845

4. Louwers Y.V.; Laven J.S.E.; Characteristics of polycystic ovary syndrome throughout life. Ther Adv Reprod Health 2020,14,2633494120911038

5. Doroszewska K.; Milewicz T.; Mrozińska, S.; Janeczko, J.; Rokicki, R.; Janeczko, M.; Warzecha, D.; Marianowski, P. Blood pressure in postmenopausal women with a history of polycystic ovary syndrome. Przegl Menopauz 2019,18(2),94-98